GCATx is developing novel therapies for hematology/oncology indications. The company acquires intellectual property from leading academic research institutions covering novel genes that harbor activating (driver) mutations which cause or promote disease in cancer patients.
Management team is experienced in technical, strategic and tactical aspects germane to science-driven target selection and data-driven pipeline development.
GCATx is developing novel drug candidates for resistant leukemias, with initial focus on Acute Lymphoblastic Leukemia (ALL).
Mutations in the target result in chemo-resistance, early relapse, and poor prognosis.